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Analysis of tumour contours and radiotherapy planning of “on-trial” 
patients undergoing chemoradiotherapy (CRT) in SCALOP trial: does 
pre-trial Radiotherapy Quality Assurance (RTQA) improve the 
quality of “on-trial” radiotherapy? 
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Background: The SCALOP trial tested the safety and efficacy of 
gemcitabine (Gem) versus capecitabine (Cap) based CRT following 
induction chemotherapy and showed that GemRT was associated 
with greater toxicity and worse survival1. The evaluation of 
investigator-delineated volumes and plan assessment from the pre-
trial RTQA program using a single benchmark case showed 
considerable variation in gross tumour volume (GTV) outlines but 
no major deviations in RT planning2.  The contours and RT planning 
of on-trial patients have now been centrally reviewed and is 
presented. 
 
Materials and Methods: Retrospective central review of planning 
CT scans of patients undergoing RT as part of SCALOP trial was 
undertaken. The central review team consisted of two radiation 
oncologists and a radiologist. Only IV-contrasted planning scans of 
good diagnostic quality were included, and tumours were re-
outlined (gsGTV). Planning target volume (gsPTV) was generated as 
per trial protocol. The accuracy of investigators’ GTV (iGTV) and PTV 
(iPTV) was compared qualitatively and geometric analyses were 
performed using the Jaccard Conformity Index (JCI) and 
Geographical Miss Index (GMI). The RT plans of on-trial patients 
were also centrally reviewed against pre-defined protocol 
constraints. 
Results: Planning scans from 64 (of 74 randomised patients) were 
suitable for analysis. The median whole volume JCI (±SD) of the 
iGTVs (compared to gsGTV) was 0.6±0.19, and the median 
GMI(±SD) was 0.1±0.2. In 1 case, the tumour was completely 
missed by the investigator in 3 other cases, GMI was >0.5 
(implying at least 50% tumour miss). For iPTVs, the median JCI was 
0.8±0.17 and the median GMI was 0.04±0.13.  There was good 
compliance with dose constraints and major deviations occurred in 
only 4.5% of the patients, with no case exceeding organ-at-risk 
constraints.  
Conclusions: This is the first comprehensive on-trial RTTQA study 
in a prospective pancreatic trial. Pre-trial RTQA is likely to have 
ensured high level of protocol adherence. The JCI and GMI obtained 
during the trial were consistent with that obtained at pre-trial QA. 
However in a proportion of patients, investigator contouring was still 
unsatisfactory, and our findings emphasize the need for performing 
detailed outlining workshops and real-time central review of 
delineations in pancreatic trials.  
 
 
 
 
 
